MedTrace Logo

Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab

NCT07151508 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2025-09-05

No results posted yet for this study

Summary

In this study, we describe our experience with secukinumab (IL-17A inhibitor) and dupilumab (IL-4/IL-13 inhibitor) treatment of a group of pediatric patients with severe Neterton syndrome.

Conditions

  • Neterton Syndrome

Interventions

DEVICE

Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age

Secukinumab was administered in a weight-adapted dosing regimen equivalent to that used in clinical trials for psoriasis: 75 mg for less than 25 kg,150 mg for 25 to 50 kg, and 300 mg for greater than 50 kg at baseline and weeks1,2,3, and 4 and monthly there after. Dupilumab was administered at a dose dependent on the patient's weight and age in accordance with the instructions.

Sponsors & Collaborators

  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology

    lead OTHER

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-19
Primary Completion
2024-12-25
Completion
2025-01-10

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07151508 on ClinicalTrials.gov